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Introduction
The life time risk of developing ovarian cancer (OC) 
is 1.4%. In 2016, 752 Belgian women were diagnosed 
with OC at a mean age of 65.6 years (Belgian Cancer 
Registry 2016, 2016). OC is the 8th (2%) most 
prevalent cancer and the 5th (6%) most common 
cause of cancer-related death among Belgian women 
(Belgian Cancer Registry 2015, 2015). The past 2 
decades the 5-year survival hasn’t changed and is 
around 44 % (Belgian Cancer Registry 2015, 2015; 
Belgian Cancer Registry 2016, 2016). In the same 
period the Belgian Cancer Registry indicated a 2.9 
decline in incidence (the age-standardised incidence 
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Abstract
Ovarian cancer (OC), is a disease difficult to diagnose in an early stage implicating a poor prognosis. The 5-year 
overall survival in Belgium has not changed in the last 18 years and remains 44 %. There is no effective screening 
method (secondary prevention) to detect ovarian cancer at an early stage. Primary prevention of ovarian cancer 
came in the picture through the paradigm shift that the fallopian tube is often the origin of ovarian cancer and 
not the ovary itself. Opportunistic bilateral salpingectomy (OBS) during benign gynaecological and obstetric 
surgery might have the potential to reduce the risk of ovarian cancer by as much as 65 %. Bilateral risk-reducing 
salpingectomy during a benign procedure is feasible, safe, appears to have no impact on the ovarian function and 
seems to be cost effective. The key question is whether we should wait for a RCT or implement OBS directly in our 
daily practice. Guidelines regarding OBS within our societies are therefore urgently needed.  Our recommendation 
is to inform all women without a child wish, undergoing a benign gynaecological or obstetrical surgical procedure 
about the pro’s and the con’s of OBS and advise a bilateral salpingectomy. Furthermore, there is an urgent need 
for a prospective registry of OBS. The present article is the consensus text of the Flemish Society of Obstetrics and 
Gynaecology (VVOG) regarding OBS.
Key words: salpingectomy, ovarian cancer, risk-reducing, reduction, prevention, menopause, opportunistic, 
prophylactic, benefits, risk, safety.
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rates in 2004 was 9.7 and in 2016 it became 6.8). For 
2025 it is expected that age-standardized rate will be 
5.6 [CI 95 % 5.1;6.1], this translates into 716 [95 % 
CI 658;774] females who will receive the diagnosis 
of OC (Belgian Cancer Registry 2016, 2016). The 
decline can be partially contributed to the use of oral 
contraceptives and hormonal IUDs. 
The majority of the patients present in an advanced 
stage and the stage distribution in the period 2004 
– 2016 has not changed (Table I) (Belgian Cancer 
Registry 2016, 2016). Based on recent molecular 
and genetic data it became apparent that epithelial 
OC is a heterogenic disease. Epithelial OC has 
therefore been divided into 2 types. Type 1 includes 
mucinous, endometrioid and clear cell carcinomas, 
while type 2 includes serous carcinomas and 
adenocarcinoma NOS (not otherwise specified). 
Tumour subtypes have an important influence on 
stage presentation at diagnosis and survival. Type 2 
are mainly (>75%) diagnosed in an advanced stage, 
while type 1 are mainly (>65%) diagnosed in an 
early stage (Table I) (Belgian Cancer Registry 2015, 
2015).  The histological subtype of OC division is 
very unequal with one fifth being type 1 and four 
fifths being type 2 (Table I). The subtype incidence 
has changed slowly the last 14 years and at present 
for serous carcinoma it is 4 per 100.000 while for 
each of the other cancers it is below 1 per 100.000. 
The primary reason for the high mortality in OC 
is the detection of the disease in an advanced stage. 
When OC is detected in stage I the patient can be 
cured in 90 % of the cases. Unfortunately, today there 
is no adequate screening (secondary prevention) for 
OC in asymptomatic women with an average risk on 
OC. The results of the randomised controlled trials 
and meta-analyses are clear: different screening 
modalities (transvaginal ultrasound, cancer antigen 
125 (CA-125) testing, or their combination) did not 
lead to a reduction in mortality (Reade et al., 2013). 
On the contrary screening asymptomatic women 
will lead to an increased morbidity due to screen-
induced explorative surgery and related psychologic 
distress (Elias et al., 2018; Henderson et al., 2018; 
Reade et al., 2013). In women with a proven high 
genetic risk of developing ovarian, peritoneal or 
tubal cancer it is considered established practice to 
offer a prophylactic risk-reducing bilateral salpingo-
oophorectomy (PBSO) after completion of the child 
wish (primary prevention). Removing the ovaries 
and tubes is very effective in reducing ovarian, 
peritoneal and tubal cancer, but could have a 
morbidity related to premature onset of menopause. 
The morbidity can be reduced by hormonal 
replacement therapy until the age of natural 
menopause. The morbidity depends of course when 
the ovaries are removed.  For BRCA2, RAD51C 
and BRIP1 the surgery can be performed relatively 
close to menopause. A PBSO on the otherhand for 
BRCA1 should be advised at a young age. 
Histologic findings from these PBSO patients 
revealed that some women had precancerous lesions 
in the fimbriae (tubal intraepithelial carcinoma or 
TIC) (Crum et al., 2007b, 2007a; Kim et al., 2018). 
The latter appeared particularly true for serous tubal 
intraepithelial carcinoma (STIC), which is assumed 
to be a precursor of high-grade serous cancer 
(HGSC). These findings caused a paradigm shift as 
the fallopian tube epithelium rather than the ovarian 
epithelial surface was regarded as the origin of 
epithelial high-grade serous OC (J. Kim et al., 2018). 
Dicer- Pten DKO (Double Knock Out) mice models 
showed that removing the fallopian tube could 
prevent the development of OC (Kim et al., 2012). 
Based on these clinical and laboratory findings 
the idea arose that primary prevention by bilateral 
salpingectomy could reduce the incidence of OC in 
women with an average risk of OC. Presentations 
and discussions at national and international 
meetings in the low countries regarding this topic 
indicated the necessity for a consensus guideline 
in daily practice (Tjalma, 2018, 2017). This article 
will describe the rationale for opportunistic bilateral 
salpingectomy (OBS) during benign gynaecological 
and obstetric surgery. The goal is to establish a 
consensus regarding OBS among members of the 
Flemish Society of Obstetrics and Gynaecology. 
Origin of ovarian cancer according to subtype 
OC can be divided into two types (Table I) 
(Dhakal et al., 2017). The clinical behaviour 
of the types reflects their genetic set-up and 
immunohistochemical features (Piszczek et al., 
2018). In OC pathology, unlike most cancers that 
become less differentiated during their neoplastic 
makeover, advanced epithelial OC ovarian display 
four distinct histological types that resemble the 
well-differentiated normal cells within the Mullerian 
system: serous type (fallopian tube origin), 
endometrioid type (endometrial origin), mucinous 
type (endocervical origin), and clear cell type 
(vaginal epithelial origin). OC from the Mullerian 
system originate from the ovary. The high-grade 
serous carcinomas (HGSC) originate from the STIC 
in the distal end of the tube (fimbriae) and not from 
the ovary. This is supported by data that no STIC 
or precursor lesions were found on the ovaries or 
peritoneum (Callahan et al., 2007; Cass et al., 2005; 
Kindelberger et al., 2007; Mittal et al., 2016; Piek 
et al., 2001). The shared sequence specific TP52 
mutations by STICs and metastatic HGSCs and 
the shared molecular profiling by HGSC and the 
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by a significant reduced incidence of endometrioid 
(RR = 0.60, CI  = 0.41–0.88) and clear cell cancer 
(RR = 0.35, CI = 0.18–0.69) after tubal ligation and 
that there also is a significant reduced risk (43%) of 
clear cell type ovarian cancer after a hysterectomy 
(RR = 0.57, CI = 0.36–0.88) (Wentzensen et al., 
2016). There could also be a protective role for a 
hormonal IUD. A hormonal IUD induces a high 
incidence of amenorrhea, subsequently a very low 
rate of retrograde menses and less endometriosis. 
Performing an operative hysteroscopy on the 
otherhand, provokes transtubal blood loss and could 
be therefore be regarded as iatrogenic retrograde 
menses. Theoretically this could also increase the 
risk of OC. 
 
Clinical data regarding the risk-reducing effect 
of tubal ligation and hysterectomy with bilateral 
salpingectomy
The retrograde menstruation can be blocked by tubal 
ligation, hysterectomy and bilateral salpingectomy 
with a significant reduction in the number of 
endometrioid and clear cell type OC as mentioned 
earlier (Wentzensen et al., 2016). In Belgium these 
cancers represent respectively 8 % and 5 % of all 
epithelial ovarian cancers. Additionally, the lack of 
decreased incidence of HGSC after a tubal ligation 
(RR=0.91;  CU = 0.79-1.06) reflects the preservation 
of fimbriae in tubal ligation. Furthermore, the 
Ovarian Cancer Cohort Consortium analysis 
among 1.300.000 women showed a reduction of 
the overall incidence of OC by 18% (RR = 0.82, 
CI = 0.73-0.93). Hysterectomy however had no 
impact on the overall incidence of OC (RR = 0.96, 
CI = 0.89-1.03). A Swedish nationwide population-
based study which looked at 98026 hysterectomies 
and OC risk showed a significant reduction in OC 
after hysterectomy  (HR  =  0.79;  CI =  0.70–0.88) 
(Falconer et al., 2015). The difference in risk 
reduction by hysterectomy between the two studies 
fallopian tube further support this finding (Carlson 
et al., 2008; Chene et al., 2013; Kim et al., 2018; 
Kindelberger et al., 2007; Kurman and Shih, 2011; 
Labidi-Galy et al., 2017; Lee et al., 2007; Mallen et 
al., 2018; Marquez et al., 2005; Mehrad et al., 2010; 
Przybycin et al., 2010). Further proof is given by the 
finding that biomarkers of HGSC are more inclined 
to relate to those of fallopian tube than to ovarian or 
peritoneal tissue (Erickson et al., 2013; Kurman and 
Shih, 2011; Mittal et al., 2016; Piszczek et al., 2018). 
The STICs transform into an invasive tubal cancer 
and by direct implantation they cause  metastasis 
on the ovary and/or peritoneum (McCluggage et al., 
2017; Mittal et al., 2016) .
It is believed that ovarian and peritoneal 
endometriosis are caused by the direct implantation 
of endometrial tissue. Whereas retrograde 
menstruation (blood and endometrial cells 
entering the peritoneal cavity through the fallopian 
tubes) occurs in about 90% of women, other 
mechanisms such as immune dysfunction and/or 
endometrial stem cells are probably involved in the 
implantation of endometrial cells and subsequent 
lesion formation. The endometriotic lesions can 
transform into atypical endometriosis and then into 
cancer. Cancers associated with endometriosis are 
endometrioid - and clear cell cancers. 
Endometriosis is not linked to an increased 
risk of serous or mucinous OC. Data that the 
PTEN, PI3KCA and ARIDIA mutations in the 
atypical endometriotic lesions are identical with 
endometrioid and clear cell type ovarian cancer, 
support this hypothesis (Wiegand et al., 2010). The 
Ovarian Cancer Cohort Consortium analysis also 
supports this theory as women with endometriosis 
have an increased risk for the development of 
endometrioid (RR = 2.32, CI = 1.36–3.95) and 
clear cell (RR = 2.87, CI = 1.53–5.39) ovarian 
cancer (Wentzensen et al., 2016). Furthermore 
the link between retrograde menstruation and 
endometriosis related types of cancers is confirmed 
        Stage division  
      I  II  III  IV
OC in general   100 %  24 %  7 %  37 %  32 %
OC Subtypes 
Type 1 OC   22 %   
- Mucinous  9 %  71 %  4 %  14 %  12 %
- Endometrioid      8 %  61 %  11 %  18 %  11 %
- Clear cell   5 %  54 %  9 %  24 %  14 %
Type 2 OC   78 %
- Serous carcinomas  68 %  13 %  9 %  47 %  31 %
- Adenocarcinoma NOS 10 %  16 %  3 %  39 %  44 %
Table I. — OC in general, OC subtypes and stage distribution.
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is a reflection that some surgeons remove the tubes 
routinely during a hysterectomy and others don’t. 
A bilateral salpingectomy would reduce the 
number of adenocarcinomas NOS (not otherwise 
specified) and serous carcinomas. In Belgium these 
cancers represent respectively 10 % and 68 % of 
all epithelial OC. A recent meta-analysis studied the 
impact of bilateral salpingectomy on OC reduction 
in the general population (Yoon et al., 2016a). This 
meta-analysis includes one cohort study and two 
population-based case-control studies (Lessard-
Anderson et al., 2014; Madsen et al., 2015; Falconer 
et al., 2015). In total 3509 patients undergoing 
bilateral salpingectomy and 5.655.702 controls who 
did not undergo salpingectomy were included (Yoon 
et al., 2016a). Over the combined study period, 29 
of the 3509 OBS patients developed OC compared 
with 44.006 of the 5.655.702 without salpingectomy. 
The results revealed that there is a 49% reduction 
in OC after an OBS (OR=0.51; CI = 0.35-0.75). 
On the contrary, while one study claimed no effect 
(Lessard-Anderson et al., 2014), one study showed 
a reduction of 42 % (OR = 0.58, CI = 0.36-0.95) 
(Madsen et al., 2015)  and the largest study revealed 
a reduction of 65 % (HR = 0.35; CI = 0.17-0.73) 
(Falconer et al., 2015). Modelling studies showed 
that if the fallopian tubes were removed at the time 
of every hysterectomy and sterilization procedure 
then a potential reduction in the rate of HGSC of 
40% over the next 20 years is to be expected for the 
operated women (Salvador et al., 2017). 
Technique of OBS in order not to compromise 
the blood supply
Preserving the ovarian function after an OBS is 
important. Premature menopause (before age 40) 
or early menopause (between 40 and 45 years) has 
been associated with an increased risk of coronary 
heart disease (CHD), stroke, glaucoma, cognitive 
impairment, dementia, Parkinson, osteoporosis, 
psychiatric diseases, sexual dysfunction, mood 
disorders and increased overall mortality (Faubion 
et al., 2015). Removing the ovaries during a 
hysterectomy before 47.5 years will reduce mortality 
related to ovarian and breast cancer (Parker et al., 
2013). However a  long-term follow-up cohort 
study of 30.117 women followed over 28 years 
showed that these benefits were neutralised by the 
significantly increased risks of dying from other 
causes: a 23% increase in CHD mortality, a 29% 
increase in lung cancer mortality, a 49% increase in 
colorectal cancer mortality and a 13% increase in 
all-cause mortality (Parker et al., 2013).  Preserving 
the ovaries in women undergoing hysterectomy until 
the age of 55 has been associated with a mortality 
reduction of 8.5 % at the age of 80 (Parker et al., 
2009). For this reason, hormonal therapy in women 
undergoing PBSO is recommended at least until the 
median age of the natural menopause (age 51 years).
In order to study the effect of OBS on the ovarian 
function it is particularly interesting to look into a 
group of premenopausal women undergoing ovarian 
stimulation as part of an IVF treatment after bilateral 
salpingectomy for tubal pathology. Ovarian function 
can be measured by looking at the ovarian follicle 
response, ovarian response to hyperstimulation, the 
ovarian reserve based on serum FSH and serum 
anti-Müllerian hormone (AMH) level. s-AMH is an 
accurate predictor of individual time-to-menopause) 
(Dólleman et al., 2014).
A recent meta-analysis (n = 1.482; 657 OBS 
and 825 no OBS) looking at the ovarian response 
before and after OBS in patients with IVF treatment 
showed there was no significant difference between 
the two groups regarding the peak E2 level, the 
total gonadotropin dose used for stimulation and the 
number of oocytes retrieved (Yoon et al., 2016b). 
Additionally, the number of pregnancies before and 
after OBS salpingectomy did not differ significantly. 
Another meta-analysis (n = 4.828) looked at the 
ovarian response to hyperstimulation during IVF 
before and after OBS (Fan and Ma, 2016). After 
OBS the total dose of gonadotropin was significantly 
increased, the number of oocytes retrieved was 
significantly decreased and the FSH level was 
significantly increased. The conclusion of this meta-
analysis was that OBS impaired ovarian response to 
hyperstimulation during IVF.
In a retrospective study (n = 198) the serum AMH 
level and FSH level were compared in women with 
or without an OBS during IVF treatment  (Ye et 
al., 2015). After OBS the mean AMH level was 
significantly lower and the mean FSH level was 
significantly higher. These results suggest that 
OBS is associated with decreased ovarian reserve. 
In the study there were no significant differences 
in duration of gonadotropin therapy, amount of 
gonadotropin used, oestradiol level on the human 
chorionic gonadotropin injection day, thickness 
of the endometrium, number of oocytes retrieved, 
number of 2-pronuclei, viable embryos, and good 
quality embryos. 
In a retrospective study looking at premenopausal 
women undergoing a hysterectomy with or without 
OBS there were no differences after 3 months 
in AMH, FSH and AFC (antral follicle count), 
mean ovarian diameters and peak systolic velocity 
(Morelli et al., 2013a). A pilot RCT (n=30; mean age 
37 years) showed that OBS during a laparoscopic 
hysterectomy did not have an effect on the AMH 
levels three months after surgery (Findley et al., 
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Safety of OBS
Several retrospective studies have looked at 
the safety and feasibility of OBS at the time of 
gynaecologic surgery. The two largest studies from 
Canada and the USA, evaluated respectively 43,932 
and 425,180 women (McAlpine et al., 2014; Hanley 
et al., 2017). The studies showed no increased 
risk for peri- and postoperative complications, 
blood transfusions, length of hospital stay in 
days, postoperative infections or readmissions 
when an OBS was additionally performed during 
a hysterectomy (Berlit et al., 2013; Findley et al., 
2013; Garcia et al., 2016; Ghezzi et al., 2009; Hanley 
et al., 2017; McAlpine et al., 2014; Minig et al., 
2015; Morelli et al., 2013b; Song et al., 2017; Till 
et al., 2018; Vorwergk et al., 2014; Westberg et al., 
2017). A register cohort study showed a statistically 
significant, though clinically irrelevant difference, 
in hospital stay of 2.5 hours between hysterectomy 
with or without BSO (Collins et al., 2019). The 
same group also reported a small but significant 
reduced amount of blood loss in the OBS group 
(-20 ml, CI = -40 to -0.1) (Collins et al., 2019). In 
addition the OBS group had significantly more 
minor complications after one year when adjusted 
for surgical route, BMI and smoking status (adjusted 
RR = 1.35; CI = 1.01 to 1.83) (Collins et al., 2019). 
However, if previous salpingitis was added then 
there was no longer a significant difference. There 
were no differences in reported severe complications 
overall. One study in which 540 laparoscopically 
assisted vaginal hysterectomies were compared 
with OBS (n=127) or without (n=413) revealed 
that there was a significant increased rate of benign 
adnexal pathology when the tubes were left behind 
(Vorwergk et al., 2014). This leads to a significant 
increase in surgical interventions in the non-OBS 
group compared to the OBS group (12.56 vs. 4.16 
%; p=0.04) (Vorwergk et al., 2014). 
The overwhelming majority of the studies didn’t 
show a difference in infection rate in the direct 
postoperative period. Benign tubal problems in 
general are rare. The annual prevalence of adnexal 
torsion is about 2 to 6 % (Sasaki and Miller, 2014). 
Rarely the fallopian tube will twist on its own, 
when it does it is usually enlarged (hydrosalpinx, 
pyosalpinx, hematosalpinx), or abnormally long, or 
previously ligated or associated with adhesions or 
paratubal cysts (Sasaki and Miller, 2014; Tjalma, 
2017). The benefits of performing an OBS besides 
the already mentioned reduction in ovarian cancer 
are reductions in postoperative tubal prolapses, 
postoperative infections, torsions, benign and 
malignant tubal diseases (Basu and Ward, 2007; 
Ghezzi et al., 2009; Morse et al., 2002; Tjalma, 
2013). A larger RCT (n = 68; mean age 43 years) 
revealed that 3 months post-surgery the AMH levels 
in both groups were significantly lower than the 
preoperative AMH levels (Kim et al., 2018). There 
were however no significant differences between the 
both groups. In a larger multicentre RCT (n=104; 
age mean 44 years) there was no difference in pre-
surgery and 6 months post-surgery AMH levels 
(Van Lieshout et al., 2018). The latter three studies 
showed that on the short term (3 to 6 months 
postoperative) at least there is no negative effect of 
OBS on the ovarian function after hysterectomy. 
The impact on menopausal symptoms one year 
after a hysterectomy with or without OBS was 
assessed in a retrospective observational cohort study 
(Collins et al., 2019). The menopausal symptoms 
were registered by the patients in questionnaires 
preoperatively and at one year postoperatively. 
Menopausal symptoms like hot flushes, sweats 
or palpitations were questioned. For this analysis 
only data of 4906 women could be used out of 
the 23369 women in the register. Preoperatively 
there was no difference between the two groups. 
The overall analysis showed a significant increase 
in menopausal symptoms in the group who had a 
hysterectomy with OBS (RR = 1.29; CI = 1.04-
1.60 and the adjusted RR was 1.33; CI = 1.04-1.69) 
(Collins et al., 2019). However, in the age-stratified 
adjusted analysis only women at the age of 44-69 
years remain at significant risk of menopausal 
symptoms one year after OBS (adjusted RR = 1.53; 
CI = 1.06-2.20) (Collins et al., 2019). 
The long term effects (3 to 5 years postoperative) 
of OBS on ovarian function have been described 
in an observational study  (Venturella et al., 2017). 
In this study the ovarian function/age was assessed 
through OvAge. The latter is a statistical model 
that combines AMH, FSH, 3-dimensional AFC, 
vascular index, flow index, and vascular flow index 
values. The mean age at surgery and an OvAge at 
follow-up was respectively 45,9 and 49,3 years. The 
conclusion of this study was that adding OBS to a 
hysterectomy in the late reproductive years did not 
have negative effects on ovarian function 5 years 
after surgery. 
In ‘older’ women (> 40 years) with or without 
an OBS there is already evidence of diminished 
ovarian reserve. Menopausal symptoms appear to be 
increased in the OBS group of 44-49 years, but this 
is not supported by surrogate markers like AMH, 
FSH, oestradiol or ultrasound (US). In these older 
women there appears to be no impact on the ovarian 
function based on these surrogate markers in the 
short- (3 months) and the long term (5 years). 
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their short term and long term morbidity. Sometimes 
performing an OBS in these cases could mean 
changing the route of access (most often in case of 
a vaginal approach). A medical decision should be 
made at that time whether or not to change the route 
of access or to abandon the plan of OBS.  
Cost effectiveness
 
Several models examined the costs and benefits 
of OBS during hysterectomy, during caesarean 
delivery or surgery for permanent contraception. 
(Kwon et al., 2015; Dilley et al., 2017; Cadish et al., 
2017; Subramaniam et al., 2019, 2018; Venkatesh 
et al., 2019). These studies all concluded that it is 
a cost-saving procedure. Prospective studies with 
long term follow-up are needed to measure the cost-
effectiveness for the health care system.   
Consensus from other societies
OBS prevents retrograde menstruation and removes 
the fimbriae. OBS at the time of surgery for benign 
gynaecological diseases or sterilization could 
decrease the risk of ovarian cancer by as much 
as 65% (Falconer et al., 2015; Kho and Wechter, 
2017; Piszczek et al., 2018). The first society to 
have a consensus regarding OBS  was the Society 
of Gynaecologic  Oncologists  of  Canada, with a 
consensus statement in September 2011  (SGOC, 
2011; Salvador et al., 2017).  Since then several 
societies have revealed consensus statements 
regarding the value of OBS during benign 
gynaecologic surgery (Table II). Eleven statements 
are in favour of OBS and five statements are 
ambivalent (Table II). At present, 2019, only a small 
minority (11%) of FIGO members have statements 
on opportunistic prophylactic salpingectomy 
(Ntoumanoglou-Schuiki et al., 2018). Consensus 
statements have a major impact in daily practice. 
After the first consensus statement publications in 
Canada and the USA regarding the value of OBS 
in the prevention of OC the uptake has increased 
considerably. In British Colombia (2008-2011) the 
uptake of hysterectomy with OBS rose from 5% 
(2008)  to 35 % (2011) and in the USA the increase 
was 371 % in the period 2008-2013  (Hanley et 
al., 2017; McAlpine et al., 2014). In some health 
delivery systems like Kaiser this has led to an OBS 
of 73 % during a benign  hysterectomy (Garcia et 
al., 2016).
In the Canadian study there was an increase in 
OBS for sterilization from 0.5 to 33% (McAlpine et 
al., 2014). By 2013  75 % of all benign hysterectomies 
had an OBS and 48 % of all sterilizations were OBS 
(Hanley et al., 2015). In Sweden the uptake of OBS 
2003; Vorwergk et al., 2014). Data from the Danish 
cohort study showed that women who have had a 
hysterectomy without an OBS (n=6456) or who 
have had a sterilization but no OBS had a more than 
doubled risk of additional tubal surgery, as the OR 
are respectively 2.13 (CI = 1.88 to 2.42) and 2.42 
(2.21 to 2.64) (Guldberg et al., 2013). 
In one large study looking at the duration of 
surgery, performing an OBS during a hysterectomy 
showed significant increase in the operating time 
regardless which route (12 minutes; p < 0.001) (Till 
et al., 2018) (16 minutes; p < 0.001) (McAlpine et al., 
2014). A recent RCT comparing OBS and bilateral 
tubal ligations at the time of caesarean delivery in 
women desiring permanent contraception, showed 
that an OBS added 15 minutes to the total operating 
time (p = 0.004) (Subramaniam et al., 2018). 
Likewise, performing an OBS instead of tubal 
ligation took also significantly longer (10 minutes; p 
< 0.001) (McAlpine et al., 2014). All other reported 
studies showed there was no significant difference 
in the operating time when an additional OBS was 
performed (Berlit et al., 2013; Findley et al., 2013; 
Garcia et al., 2016; Ghezzi et al., 2009; Minig et 
al., 2015; Morelli et al., 2013b; Song et al., 2017; 
Vorwergk et al., 2014).
In a study looking at immediate and short-term 
complications and surgical duration among women 
having laparoscopic salpingectomy (n=81) or tubal 
occlusion (n=68) for female sterilization there was 
no difference in complication rate, but the average 
surgical time was 6 min longer for salpingectomy 
compared to occlusive methods (44±13 min versus 
38±15 min, respectively, p=0.018) (Westberg 
et al., 2017). A downside in changing from a 
tubal sterilization to an OBS, could mean adding 
additional port(s) (three ports instead of one or two) 
and it could also include the use of another surgical 
instrument with its own energy and complication 
rate. When OBS is considered in patients for 
sterilization, we need to underline the definite 
character of this technique as 2-5% of patients 
will show regret later in life, especially in younger 
patients (younger than 40). 
In conclusion, adding an OBS to an abdominal 
or laparoscopic hysterectomy doesn’t increase 
the complications rates. It may however slightly 
extend the operating time. In exceptional cases, and 
certainly during vaginal hysterectomy, removal of 
the fallopian tubes is challenging. In experienced 
hands routine removal of free mobile fallopian tubes 
during abdominal or laparoscopic surgery is easily 
done. Removal of diseased fallopian tubes whether 
or not adherent to other pelvic structures could 
increase operation time and the complication rate. 
For this reason, it is important to registrate OBS and 
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indicates, except for one retrospective study, that 
there seems to be no impact on the ovarian function/
reserve when the blood supply was respected. 
At present there is one ongoing randomized 
controlled trial looking at the outcome of OBS 
in asymptomatic women with an average risk 
on OC. This is the HOPPSA or Hysterectomy 
and OPPortunistic SAlpingectomy study (NCT 
03045965; ClinicalTrials.gov). The HOPPSA is a 
register-based randomized controlled trial (R-RCT), 
with the objective to examine if OBS compared with 
no OBS, at the time of hysterectomy for a benign 
reason, has no increased risk of complications, has 
no negative side effects on ovarian function and 
subsequent cardiovascular disease or incidence of 
fractures, and implies a reduced risk of subsequent 
OC. Randomization and follow-up will be conducted 
within national registers (https://clinicaltrials.gov/
ct2/show/NCT03045965). 
The trial has three primary outcome measures: 1. 
8 weeks post-operative surgical complication rate; 2. 
change in menopausal symptom score or the effects 
on ovarian function at 1 year; 3. the risk reduction 
of epithelial OC at 10 – 30 years.  The study started 
on June 1, 2017 and the estimated time of closure 
is June 1, 2020. In total 4.400 participants need to 
be randomized and it is estimated that the study is 
completed for all 3 outcome parameters in 2053! 
Guidelines regarding OBS by our society are 
urgently needed as otherwise clinicians will be 
caught up by (social) media and demands regarding 
OBS. The impact of a consensus statement by a 
society is high, but it protects both the patient, 
at the time of hysterectomy increased since 2013. In 
2012 OBS with hysterectomy in Sweden was only 
performed in 1.9%, in 2013 it was 8.9 % and in 2016 
it increased to 37.8 % (Collins et al., 2019). The 
Swedish data indicate that despite the ambivalent 
advice of the Society (SSOG) the rates of OBS are 
increasing. When you compare this to Ireland, then 
you notice that figures haven’t changed much since 
the first publications regarding the role of OBS. In 
a questionnaire 26 % of the Irish gynaecologists 
indicated that they performed an OBS in 26 % of 
the abdominal benign hysterectomies (ABH) and 
in 5.4 % of the vaginal benign hysterectomies 
(VBH) (Kamran et al., 2013).  They were willing to 
incorporate  an OBS in 90 % of the ABH and in 66 
% of the VBH  as a measure to reduce cancer risk 
(Kamran et al., 2013).  
Conclusions and Consensus statements of the 
Flemish Society of OB & GYN
 
The paradigm shift that serous OC originate from the 
fallopian tube has opened the door for OBS. High 
grade serous OC represents more than two third 
of epithelial OC and is associated with advanced 
disease stage, high incidence of disease recurrence 
and poor prognosis despite aggressive surgery and 
advanced chemotherapy.
Current available retrospective data suggest a 
49% to 65 % reduction in OC if both salpinges are 
removed. On the short term this procedure appears to 
be safe with probably a slight increase in operating 
time. On the long term all available evidence 
Table II. — Societies with a consensus regarding OBS.
Societies in favour of OBS
2011 Society of Gynaecologic  Oncologists  of  Canada (SGOC, 2011)(Salvador et al., 2017).  
2012  Finnish Society of Obstetrics and Gynaecology (FSOG, 2012), 
2012 Dansk Selskab for Obstetrik og Gynækologi  (Denmark) (FSOG, 2012)
2013,
 2015 Society of Gynaecologic Oncology  (SGO) in the United States (SGO, 2013)(Walker et al., 2015). 
2014   Royal Australian and New Zealand College of Obstetricians and Gynaecologists  (RANZCOG) (updated July 2014) 
 (RANZCOG, 2014)
2014  Royal College of Obstetricians and Gynaecologists (UK)(RCOG, 2014)
2014 Turkish Society of Gynaecologic Oncology (TSGO, 2014), 
2015 American College of Obstetricians and Gynaecologists (ACOG) (Committee on Gynecologic Practice, 2015)
2015 Austrian Society of Obstetrics and Gynaecology and Austrian Society of Pathology (ASO and ASP, 2015)
2017 Japan Society of Obstetrics and Gynaecology (Fujii et al., 2017)
2018 Korean Society of Obstetrics and Gynaecology (KSOG) (Kim et al., 2018). 
Societies with an ambivalent statements regarding OBS
2015 Norsk Gynecologisk Forening (NGF, 2015)
2015 German Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) (Pölcher et al., 2015)
2015 Swedish Society of Obstetrics and Gynaecology (SSOG, 2015)
2016 French College of Obstetrics and Gynaecology (Deffieux et al., 2016)
2018 National Comprehensive Cancer Network (NCCN, 2018). 
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